Clinical Trials Logo

Urticaria clinical trials

View clinical trials related to Urticaria.

Filter by:

NCT ID: NCT06295302 Recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria

Start date: December 13, 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-bind and placebo-controlled phase IIa dose-finding study to assess the safety and efficacy of HWH486 in adults with chronic spontaneous urticaria (CSU). In addition, the pharmacokinetic characteristics will also be investigated.

NCT ID: NCT06294288 Active, not recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD).

NCT ID: NCT06268470 Active, not recruiting - Chronic Urticaria Clinical Trials

Antiplatelet Therapy in Chronic Urticaria

Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

This study compares the combination of antiplatelets and antihistamine versus antihistamine alone for the treatment of chronic spontaneous urticaria

NCT ID: NCT06250400 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)

Start date: March 31, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to study patients with chronic spontaneous urticaria. The main question it aims to answer is the efficacy and safety of histamine human immunoglobulin (ShuYangMinNing) in the treatment of chronic spontaneous urticaria.

NCT ID: NCT06228560 Recruiting - Clinical trials for Chronic Spontaneous Urticaria

Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Start date: January 25, 2024
Phase: Phase 2
Study type: Interventional

The study is a Phase II, multicenter, randomized, double-blind study to evaluatethe efficacy and safety of LP-003 administered subcutaneously as an add-on therapy for the treatment of adult patients aged 18-75 who have been diagnosed with refractory CSU and who remain symptomatic despitestandard-dose H1 antihistamine treatment.

NCT ID: NCT06210698 Not yet recruiting - Urticaria Clinical Trials

Angioedema Biomarker Research Study

Start date: January 15, 2024
Phase:
Study type: Observational

This clinical trial aims to evaluate and compare novel and commercially available diagnostic assays through blood tests for the differential diagnosis and comprehensive assessment of patients experiencing recurrent angioedema attacks, including both urticarial and non-urticarial angioedema. The primary objective is to assess the efficiency of novel diagnostic assays, both individually and in combination, in comparison to currently available commercial tests. The ultimate goal is to establish the feasibility of developing an affordable and accurate laboratory test capable of diagnosing the diverse etiological manifestations of angioedema.

NCT ID: NCT06201780 Recruiting - Clinical trials for Cholinergic Urticaria

Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With Cholinergic Urticaria

Start date: December 15, 2023
Phase: N/A
Study type: Interventional

Cholinergic Urticaria (CholU) is as a subtype of CIndU caused by an increase in the core body temperature, such as to activate the sweating reflex. It can occur in response to physical exercise, hot bathing and/or emotional stress. Clinically it appears as pinpointing and highly pruritic wheals with surrounding erythema, CholU can be accompanied by severe symptoms such as angioedema, respiratory symptoms or anaphylaxi CholU is frequently associated with atopic dermatitis (AD) The JAK-STAT is a mast cell (MC) signaling pathway activated downstream of IgE and IL-3 with important roles in MC homeostasis via regulation of proliferation, survival, and release of mediators. JAK-STAT activation is associated with polarization toward Th2, B cell isotype switching to IgE production, and IgE-dependent degranulation and cytokine release . Because both IL-4 and IL-13 use the IL-4Rα as a receptor component, these cytokines activate any common signaling pathways. Both of these cytokines use Janus kinases (JAKs) to initiate signaling and activate signal transducer and activator of transcription-6 (STAT6), which is a transcription factor required for many of their biologic functions. The non-receptor protein tyrosine kinases JAK1 and JAK3 associate with the IL-4Rα and γC, respectively. The binding of IL-4 to its receptor induces the transphosphorylation of JAK1 and JAK3, an event that activates these kinases and thereby initiates the early events of signal transduction .

NCT ID: NCT06162728 Recruiting - Clinical trials for Chronic Spontaneous Urticaria

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

BEACON
Start date: November 29, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, and other pharmacodynamic (PD) parameters (such as effects on mast cells (MC), serum tryptase levels, and on allergic skin reactivity) will be investigated.

NCT ID: NCT06127992 Active, not recruiting - Urticaria Cold Clinical Trials

Non-invasive Diagnosis of Cold Urticaria

Start date: May 12, 2023
Phase: N/A
Study type: Interventional

The investigators subjected 63 patients (39 with typical Cold urticaria and 24 with atypical Cold urticaria ) and 15 healthy controls to TempTest® cold stimulation tests and critical temperature threshold assessments. Blood microcirculation photoplethysmography measurements were performed 5 min before and 10 min after the ice cube on the volar forearm.

NCT ID: NCT06108869 Suspended - Clinical trials for Chronic Spontaneous Urticaria

Improving Health and Wellbeing for People Diagnosed With Chronic Spontaneous Urticaria (CSU)

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This study aims to investigate the influence of psychosocial factors on Chronic Spontaneous Urticaria (CSU). Preliminary research suggests a potential link between stress and the experience of CSU symptoms. In light of these findings, our study offers a stress management intervention for individuals diagnosed with CSU. The intervention consists of a 6-week online course designed to cultivate effective stress management techniques, referred to as 'attention-based training (ABT).' The course asks each participant to develop their own ABT practice, along with a one-hour session per week, providing techniques that participants can use to combat stressors related to their condition.